Dual-Targeted CAR T-Cell Therapy Against EGFR and IL13Ra2 Offers Hope in Glioblastoma

Promising Early Findings for CAR T-Cell Therapy in Glioblastoma

The most common primary brain tumor in adults, glioblastoma multiforme (GBM) , is the focus of a new-generation dual-targeted CAR T-cell therapythat produced tumor shrinkage in 85% of treatment-resistant patients. For this aggressive brain cancer, for which only temporary solutions have been available for many years, these results could represent a breakthrough in immune-based treatments.

This innovative treatment was developed to recognize EGFR epitope 806 and IL13Ra2 simultaneously as two distinct surface targets, using bivalent CAR T cells . For the first time, the treatment was injected directly into patients' cerebral ventricles (ICV – intraventricular), representing another first.

🧪 Study Summary:

• Participants: 18 patients with treatment-resistant glioblastoma
• Treatment: A single dose of CAR T cells after surgery, via the ICV route delivered directly into the cerebrospinal fluid
• Results:
  • Among 13 patients with measurable disease, 11 (85%) had a reduction in tumor volume
  • Maximum shrinkage: 62%
  • 1 patient had a partial response (PR), while 1 patient had stable disease for 17 months .
• CAR T cellsremained detectable in the cerebrospinal fluid for 12 months
• All patients experienced transient fever and neurological side effects; severe side effects were limited (Grade 4 in only 1 patient)

🧭 Why Does It Matter?

Glioblastomais the most common brain tumor in adults and has aggressive biology. Despite standard treatment, most patients experience recurrence within 6–9 months, and overall survival rarely exceeds 1 year. The need for new treatment strategies is therefore greater than ever.

Dr. Stephen Bagley reported, in this phase 1 study, an 85% tumor shrinkage rate, which is regarded as a success in glioblastoma. Previously, CAR T-cell therapies had been limited to hematological cancers; this study provides evidence that CAR T cells may also be effective in solid tumors — one of the first strong signals in this setting.

🌐 What Is Planned?

• The CAR T cells now have a 3-target version under development, with the aim of achieving longer persistence in the brain
• Next year, the treatment will also begin testing in newly diagnosed patients who are in better health
• Demand from patients for the clinical trial has exceeded capacity by more than 10-fold; referrals are being made even from distant US states

💬 Expert Commentary:

“For the first time in years, we are seeing a clear tumor response in glioblastoma. This is a milestone not only for treatment, but also as proof that the immune system can now reach brain tumors.”
— Dr. Stephen Bagley, University of Pennsylvania

📌 Conclusion:

“Cold tumors” such as glioblastoma are now coming onto the immune system's radar. This new-generation dual-targeted CAR T-cell therapy against EGFR and IL13Ra2 may have provided a long-awaited glimmer of hope for glioblastoma.